Guliz Ozgun
Clinical trials sponsored by Guliz Ozgun, explained in plain language.
-
Morning vs afternoon: can timing boost kidney cancer treatment?
Disease control Not yet recruitingThis study looks at whether getting standard immunotherapy drugs (nivolumab and ipilimumab) in the morning or afternoon affects how well they work for advanced kidney cancer. About 142 adults will be randomly assigned to morning or afternoon treatment. The goal is to see if timin…
Phase: PHASE3 • Sponsor: Guliz Ozgun • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
Morning or afternoon? new study tests best time for bladder cancer treatment
Symptom relief Not yet recruitingThis study looks at whether giving standard advanced bladder cancer drugs (enfortumab vedotin and pembrolizumab) in the morning or afternoon changes how well they work or how many side effects they cause. About 224 adults with advanced bladder cancer will be randomly assigned to …
Phase: PHASE3 • Sponsor: Guliz Ozgun • Aim: Symptom relief
Last updated May 12, 2026 13:51 UTC